November 4, 2014 | Peregrine Ventures sold its 30 percent stake in Neovasc to Fidelity for $12 million, selling 2 million of their 6.7 million company shares, at $6 per share. Peregrine’s holdings in Neovasc, a company that manufactures, develops and markets cardiovascular products, are worth approx. $27.5 million, with Peregrine holding on to 4.7 million of its shares in Neovasc. Neovasc was created through a merger deal led by Peregrine Ventures in 2008, in which two of Peregrine’s companies, Neovasc and B-Ballon merged with the publicly traded Canadian company Medical Ventures Corporation.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israel Bolstering Young Startups With Angel Investor Fund
November 30, 2023

Israeli Medtech Companies Partner To Develop ‘Artificial Lung’
November 30, 2023

Cyber Startup Chosen To Secure Upcoming Tel Aviv Light Rail Line
November 29, 2023

Platform Battling Lies On Israel Expands Reach With 23 New Languages
November 29, 2023
Facebook comments